IPA2025

HOME

CONGRESS

Call for Submissions

Congress

Invited Speakers

Session Chair

Organizing Committee

Venue-SICC

Social Program

Scientific Committee

SPONSORS AND EXHIBITORS

LOCATIONS

Shanghai

How to be Here

What to do in Shanghai

Hotels

PDT IN CHINA

Visa

We sincerely extend warm welcome to you for Registration or Submission

Late-Breaking abstracts calling:
March 1 to March 31, 2025

Deadline for early bird price: March 31, 2025

About

IPA 2025

The International Photodynamic Association (IPA) was founded in 1986 to support and endorse the scientific advancement and clinical development of photomedicine, in particular in the areas of photodynamic disinfection, photodynamic therapy (PDT), photoimmunotherapy (PIT), and photodiagnosis (PD).

The IPA organizes a Biennial World Congress, providing members and non-members a unique opportunity to share and learn more about global developments and research in photodynamic therapy, photoimmunotherapy and photodiagnosis. The 19th IPA World Congress will be held at the Shanghai International Convention Center in Shanghai, China , June 10-16, 2025.

IPA 2025 Info

Conference Chair: Xiuli Wang, MD, PhD

Venue: Shanghai International Convention Center

Speakers

Keynote Speakers

Prof. Jiro Akimoto, D.M.Sci., Ph.D.

Kohsei Chuo General Hospital and Tokyo Medical University

Photodynamic Therapy for primary malignant brain tumors: 10 years' experience after insurance approval in Japan

In January 2014, photodynamic therapy (PDT) with talaporfin sodium for primary malignant brain tumors was approved by the Japanese Government as a healthcare treatment. Since then, we have developed guidelines, held hands-on workshops, produced promotional videos, presented at conferences and published papers in order to promote this safe and highly effective treatment. Ten years later, PDT is now routinely performed for malignant brain tumors at more than 30 facilities in Japan in around 200 cases per year, but it still cannot be said to have become an intra-operative adjuvant therapy with a high level of evidence.
In recent years, a number of facilities in Japan have reported on the efficacy of PDT. While each of these demonstrates the clinical efficacy of PDT, there have been reports of depression due to light shielding, transient post-operative brain edema, which were not anticipated at the time of development. The characteristics of recurrence patterns after PDT, specific pseudo-progression, and resistance mechanisms and their overcoming are also being elucidated, and some of the new knowledge on PDT has been obtained in the last decade.
In this presentation, I would like to summarize our 10 years of experience in our activities and demonstrate the current status of PDT in Japan and its future prospects.

Prof. Tayyaba Hasan, Ph.D.

Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School;
Division of Health Sciences and Technology, joint program of Harvard University - Massachusetts Institute of Technology

Photodynamic Activation in addressing barriers in the development of therapeutics

The impact of Photodynamic Therapy (PDT) in changing medical practice has been low and slow. This is the situation despite PDT having been approved for the treatment of cancer and non-cancer diseases for almost 3 decades and proven to be a minimally invasive and effective modality, sometimes when all else has failed. Perhaps we, the photodynamic community, need to think of photodynamics as a process that not only can be used for therapy as we know it, but as a much more powerful tool to overcome barriers with conventional therapeutics.
I hope to make this an analysis presentation of the promise and disappointment of PDT technology with audience participation.

Prof. Colin Hopper, M.D., FRCS(Ed), FDSRCS

University College Hospital

Global opportunities for PDT application

Adoption of PDT in the western world has been slow to gain widespread adoption. Things are however changing with the advent of antimicrobial PDT with the prospect of it having an important role in surgical site infection reduction. A natural extension of this application is in the treatment/prevention of other fungal and viral infections.
Aggressive marketing of immunotherapy has made it difficult to establish anti cancer PDT, although photoimmunotherapy might well be an exception in this regard. The exception is in dermatology where PDT is an accepted standard treatment for basal cell cancer, especially in South America.
Global health inequalities present an opportunity for PDT as a simple inexpensive treatment as shown by studies in India, Indonesia and Bolivia. Given that 100 million people worldwide do not have access to radiotherapy, there are clear opportunities for PDT application.

Prof. Luis G. Arnaut, Ph.D., Habilitation

University of Coimbra

Adventures while Attempting Clinical Translation of Photodynamic Therapy

Research in Photodynamic Therapy (PDT) generated exciting preclinical data in laboratories around the world. The high expectations raised concerning selectivity, tolerance, affordability, efficacy and synergies with immunological responses have not yet been accompanied by traction in the medical field. We report our own efforts to make PDT applications available for oncology and infectious diseases. Our approach begins with the design of photosensitizers and/or medical devices, and extends to exploratory clinical trials [1-3]. New developments making use of new illumination methods and innovative medical devices are discussed in detail.

References
[1] A. S. Amorim, Z. A. Arnaut, A. I. Mata, B. Pucelik, A. Barzowska, G. J. da Silva, M. M. Pereira, J. M. Dabrowski, L.G. Arnaut. ACS Infect. Dis., 10 (2024) 3368-3377
[2] L. G. Arnaut, M. M. Pereira. Chem. Commun., 59 (2023) 9457-9468
[3] A. C. Zangirolami, L. D. Dias, K. C. Blanco, C. S. Vinagreiro, N. M. Inada, L. G. Arnaut, M. M. Pereira, V. S. Bagnato, Proc. Natl. Acad. Sci. USA, 117 (2020) 22967-22973

Prof. Xiuli Wang, M.D., Ph.D.

Shanghai Skin Disease Hospital Affiliated to Tongji University;
Institute of photomedicine affiliated to Tongji University School of Medicine

Photodynamic therapy in dermatology

Photodynamic therapy（PDT）has been applied in dermatology for more than 30 years. The widely accepted mechanisms of PDT are primarily classified into three aspects: 1) Direct cytotoxicity to target cells through the generation of ROS. 2) Destruction of the tissue microvascular system. 3) Induction of an inflammatory response and further activating the immune system. Topical 5-aminolevulinic acid (ALA)-PDT have been approved in Europe and the United States for actinic keratosis (precancerous lesions), Bowen’s disease (squamous cell carcinoma in situ) and certain types of basal cell carcinoma. In addition, ALA-PDT is widely applied in HPV related diseases in China, especially genital warts developed in meatal regions including the urethra, cervix and vagina. Currently, genital wart is the only indication of ALA-PDT approved in China. It can not only remove visible lesions, but also clean subclinical HPV infection through field treatment, and consequently reduce the recurrence. In recent years, the application of ALA-PDT in pilosebaceous unit diseases, including acne, rosacea and hidradenitis suppurativa, has also attracted high attention. The potential mechanisms probably include the suppression of sebaceous glands in proliferation and sebum production, the bacteriostatic effect on follicular bacteria, and the modulation of inflammation and immune responses.

Prof. Jiro Akimoto, D.M.Sci., Ph.D.

Kohsei Chuo General Hospital and Tokyo Medical University

Photodynamic Therapy for primary malignant brain tumors: 10 years' experience after insurance approval in Japan

Prof. Tayyaba Hasan, Ph.D.

Photodynamic Activation in addressing barriers in the development of therapeutics

Registration

IPA 2025 registration is now open call for papers

News

News and useful informations